

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 21, 2003, 12:30:08 ; Search time 34 Seconds
(without alignments)
7.838 Million cell updates/sec

Title: SHORT-PEP
Perfect score: 16
Sequence: 1 rw 2

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 24944

Minimum DB seq length: 0
Maximum DB seq length: 5

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database :

A.Geneseq.101002.*
1: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT:*
2: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT:*
3: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT:*
4: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT:*
5: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT:*
6: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT:*
7: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT:*
8: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT:*
9: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT:*
10: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT:*
11: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT:*
12: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT:*
13: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT:*
14: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT:*
15: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT:*
16: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT:*
17: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT:*
18: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT:*
19: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT:*
20: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT:*
21: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT:*
22: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT:*
23: /SIDs2/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	16	100.0	3	15	AA198527
2	16	100.0	3	15	AA198528
3	16	100.0	3	15	AA198529
4	16	100.0	3	15	AA198530
5	16	100.0	3	15	AA198531
6	16	100.0	3	15	AA198532
7	16	100.0	3	15	AA198533
8	16	100.0	3	15	AA198534
9	16	100.0	3	15	AA198535
10	16	100.0	3	15	AA198536

11	16	100.0	3	19	AA198537
12	16	100.0	3	19	AA198538
13	16	100.0	3	19	AA198539
14	16	100.0	3	19	AA198540
15	16	100.0	3	19	AA198541
16	16	100.0	3	19	AA198542
17	16	100.0	3	19	AA198543
18	16	100.0	3	19	AA198544
19	16	100.0	3	19	AA198545
20	16	100.0	3	19	AA198546
21	16	100.0	3	19	AA198547
22	16	100.0	3	19	AA198548
23	16	100.0	3	19	AA198549
24	16	100.0	3	19	AA198550
25	16	100.0	3	19	AA198551
26	16	100.0	3	19	AA198552
27	16	100.0	3	19	AA198553
28	16	100.0	3	19	AA198554
29	16	100.0	3	19	AA198555
30	16	100.0	3	19	AA198556
31	16	100.0	3	19	AA198557
32	16	100.0	3	19	AA198558
33	16	100.0	3	19	AA198559
34	16	100.0	3	19	AA198560
35	16	100.0	3	19	AA198561
36	16	100.0	3	19	AA198562
37	16	100.0	3	19	AA198563
38	16	100.0	3	19	AA198564
39	16	100.0	3	19	AA198565
40	16	100.0	3	19	AA198566
41	16	100.0	3	19	AA198567
42	16	100.0	3	19	AA198568
43	16	100.0	3	19	AA198569
44	16	100.0	3	19	AA198570
45	16	100.0	3	19	AA198571
46	16	100.0	3	19	AA198572
47	16	100.0	3	19	AA198573
48	16	100.0	3	19	AA198574
49	16	100.0	3	19	AA198575
50	16	100.0	3	19	AA198576
51	16	100.0	3	19	AA198577
52	16	100.0	3	19	AA198578
53	16	100.0	3	19	AA198579
54	16	100.0	3	19	AA198580
55	16	100.0	3	19	AA198581
56	16	100.0	3	19	AA198582
57	16	100.0	3	19	AA198583
58	16	100.0	3	19	AA198584
59	16	100.0	3	19	AA198585
60	16	100.0	3	19	AA198586
61	16	100.0	3	19	AA198587
62	16	100.0	3	19	AA198588
63	16	100.0	3	19	AA198589
64	16	100.0	3	19	AA198590
65	16	100.0	3	19	AA198591
66	16	100.0	3	19	AA198592
67	16	100.0	3	19	AA198593
68	16	100.0	3	19	AA198594
69	16	100.0	3	19	AA198595
70	16	100.0	3	19	AA198596
71	16	100.0	3	19	AA198597
72	16	100.0	3	19	AA198598
73	16	100.0	3	19	AA198599
74	16	100.0	3	19	AA198600
75	16	100.0	3	19	AA198601
76	16	100.0	3	19	AA198602
77	16	100.0	3	19	AA198603
78	16	100.0	3	19	AA198604
79	16	100.0	3	19	AA198605
80	16	100.0	3	19	AA198606
81	16	100.0	3	19	AA198607
82	16	100.0	3	19	AA198608
83	16	100.0	3	19	AA198609

84	16	100.0	3	19	AA198610
85	16	100.0	3	19	AA198611
86	16	100.0	3	19	AA198612
87	16	100.0	3	19	AA198613
88	16	100.0	3	19	AA198614
89	16	100.0	3	19	AA198615
90	16	100.0	3	19	AA198616
91	16	100.0	3	19	AA198617
92	16	100.0	3	19	AA198618
93	16	100.0	3	19	AA198619
94	16	100.0	3	19	AA198620
95	16	100.0	3	19	AA198621
96	16	100.0	3	19	AA198622
97	16	100.0	3	19	AA198623
98	16	100.0	3	19	AA198624
99	16	100.0	3	19	AA198625
100	16	100.0	3	19	AA198626

84	16	100.0	4	22	AAG71192	Melanocortin recep
85	16	100.0	4	22	AAG71233	Melanocortin recep
86	16	100.0	4	22	AAB67268	Sexual dysfunction
87	16	100.0	4	22	AAB61544	alpha-melanocyte-s
88	16	100.0	4	22	AAB65335	Alpha melanotropin
89	16	100.0	4	23	AAU78853	Antimicrobial pept
90	16	100.0	4	23	AAU78854	Antimicrobial pept
91	16	100.0	4	23	AAU78855	Antimicrobial pept
92	16	100.0	4	23	AAU78856	Antimicrobial pept
93	16	100.0	4	23	AAU78857	Antimicrobial pept
94	16	100.0	4	23	AAU78858	Antimicrobial pept
95	16	100.0	4	23	AAU78860	Antimicrobial pept
96	16	100.0	4	23	AAU78861	Antimicrobial pept
97	16	100.0	4	23	AAU78862	Antimicrobial pept
98	16	100.0	4	23	AAU78863	Antimicrobial pept
99	16	100.0	4	23	AAU78864	Antimicrobial pept
100	16	100.0	4	23	AAU78865	Antimicrobial pept

ALIGNMENTS

RESULT 1

AAK48527
ID AAK48527 standard; peptide; 3 AA.

AC AAK48527;

DT 10-AUG-1994 (first entry)

DE Lactoferrin derived peptide #21.

KM Decomposition; lactoferrin; digestion; enzyme; pepsin; trypsin;

KW antioxidant; oxidation; inhibitor; vitamin E; ascorbic acid;

KM vitamin A; beta-carotene; superoxide dismutase; coenzyme Q;

KM lipid oxidation; foodstuff; drugs; health food; toiletries; cosmetics.

OS Bos taurus.

PN WO9403555-A.

PD 17-FEB-1994.

PF 04-AUG-1993; 93WO-JP01090.

PR 07-AUG-1992; 92JP-0211335.

PA (MORG) MORINAGA MILK IND CO LTD.

PI Bellamy WR, Fukuwatari Y, Kawase K, Shimamura S;

PI Takase M, Tokiday, Tomita M, Wakabayashi H, Yamauchi K;

DR WPI: 1994-065650/08.

PT Antioxidant peptide lactoferrin decomposition product - prevents

PT oxidation of lipid(s) in foodstuffs and drugs without affecting

PI their taste

PS Claim 3; Page 34; 47pp; Japanese.

XX The sequences given in AAK48507-37 are peptides derived by the

CC decomposition of lactoferrin, pref. by digestion with an enzyme, eg.

CC pepsin or trypsin. These peptides may be used in an antioxidant

CC composition which may also contain an oxidation inhibitor such as

CC vitamin E, ascorbic acid, vitamin A, beta-carotene, superoxide

CC dismutase or coenzyme Q. The antioxidant prevents lipid oxidation

CC in foodstuffs, drugs, health foods, toiletries and cosmetics.

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY	1	RW 2
DB	1	RW 2

RESULT 2

AAK57458
ID AAK57458 standard; Protein; 3 AA.

AC AAK57458;

DT 28-FEB-1995 (first entry)

DE Lactoferrin derived peptide #21.

KM Lactoferrin; chemical; enzymatic; hydrolysis; antimicrobial;

KM antiseptic; ischemic disease.

OS Mus musculus.

PN JP06172200-A.

PD 21-JUN-1994.

PF 08-DEC-1992; 92JP-0327738.

PR 08-DEC-1992; 92JP-0327738.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI: 1994-238662/29.

PT Brain protectant for preventing ischemic diseases without side

PT effects - comprising 31 specified peptide(s), prepd. by

PT lactoferrin hydrolysis

PS Disclosure; Page 9; 11pp; Japanese.

CC The sequences given in AAK57438-68 represent fragments of lactoferrin

CC which were derived from the full length protein by chemical or enzyme

CC hydrolysis. These peptides have brain protecting properties, as

CC well as anti-microbial activity. Compositions containing these

CC peptides may be prepared with out the addition of antisepsics, and

CC may be administered at doses of at least 10 mg for parenteral

CC administration and 100 mg for oral administration. These peptides

CC are stable, heat resistant, water soluble and may be used for the

CC prevention of ischemic diseases without side effects.

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Sequence 3 AA:

Query Match 100.0%; Score 16; DB 15; Length 3;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

XX  JP06220088-A.
PN  09-AUG-1994.
XX
PD  22-JAN-1993; 93JP-0025977.
XX
PR  22-JAN-1993; 93JP-0025977.
XX
PA  (ASAH ) ASAH KASEI KOGYO KK.
XX
DR  WPI; 1994-290911/36.
XX
PT  New tri:peptide(s) - inhibit angiotensin I converting enzyme
XX
PS  Claim 1; Page 2; 4pp; Japanese.
XX
CC  This is one of thirteen claimed tripeptides (AAR58569-R58581) which
CC  inhibit angiotensin I converting enzyme (with IC50 of 2.9-186.2
CC  micromolar). The tripeptides are incorporated into food, e.g.
CC  hamburgers.
XX
SQ  Sequence 3 AA;

Query Match      100.0%; Score 16; DB 15; Length 3;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1 RW 2
    11
DB  2 RW 3

RESULT 4
AAR58569
ID  AAR58569 standard; peptide; 3 AA.
XX
AC  AAR58569;
XX
DT  26-APR-1995 (first entry)
XX
DE  Angiotensin I converting enzyme inhibitory tripeptide LRW.
XX
KW  angiotensin converting enzyme; inhibitor; food ingredient.
XX
OS  Synthetic.
XX
PN  JP06220088-A.
XX
PD  09-AUG-1994.
XX
PF  22-JAN-1993; 93JP-0025977.
XX
PR  22-JAN-1993; 93JP-0025977.
XX
PA  (ASAH ) ASAH KASEI KOGYO KK.
XX
DR  WPI; 1994-290911/36.
XX
PT  New tri:peptide(s) - inhibit angiotensin I converting enzyme
XX
PS  Claim 1; Page 2; 4pp; Japanese.
XX
CC  This is one of thirteen claimed tripeptides (AAR58569-R58581) which
CC  inhibit angiotensin I converting enzyme (with IC50 of 2.9-186.2
CC  micromolar). The tripeptides are incorporated into food, e.g.
CC  hamburgers.
XX
SQ  Sequence 3 AA;

Query Match      100.0%; Score 16; DB 15; Length 3;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1 RW 2
    11
DB  2 RW 3

```

```

QY  1 RW 2.
    11
DB  2 RW 3

RESULT 5
AAR84695
ID  AAR84695 standard; peptide; 3 AA.
XX
AC  AAR84695;
XX
DT  13-JUN-1996 (first entry)
XX
DE  Bovine lactoferrin derived angina pectoris treating peptide.
XX
KW  Bovine lactoferrin; angina pectoris; treatment; low toxicity;
KW  no side effects; heat resistance; water solubility; stability;
KW  aqueous solution; preservative free.
XX
OS  Bos taurus.
XX
PN  JP07278011-A.
XX
PD  24-OCT-1995.
XX
PF  01-APR-1994; 94JP-0085243.
XX
PR  01-APR-1994; 94JP-0085243.
XX
PA  (MORG ) MORINAGA MILK IND CO LTD.
XX
DR  WPI; 1995-400916/51.
XX
PT  Peptide for treatment of angina pectoris - has low toxicity and is
PT  heat resistant and water soluble
XX
PS  Claim 1; Page 10; 12pp; Japanese.
XX
CC  The present peptide is a bovine lactoferrin derived, angina
CC  pectoris treatative agent. It has low toxicity and side effects,
CC  is heat resistant, water soluble and stable in an aq. soln.. It
CC  also requires no preservative.
XX
SQ  Sequence 3 AA;

Query Match      100.0%; Score 16; DB 16; Length 3;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1 RW 2
    11
DB  1 RW 2

RESULT 6
AAM00269
ID  AAM00269 standard; peptide; 3 AA.
XX
AC  AAM00269;
XX
DT  30-APR-1997 (first entry)
XX
DE  Cytokine regulatory peptide #4.
XX
KW  Cytokine regulatory peptide; disuse deconditioning; IL-10;
KW  nitric oxide; adverse drug reaction; obesity; septic shock;
KW  cancer chemotherapy; organ transplant; cachexia; cyclosporin;
KW  adult respiratory distress syndrome; ARDS; autoimmune disease;
KW  allergic reaction; anaphylaxis; arthritis; inflammatory bowel disease;
KW  diabetes; glomerulonephritis; systemic lupus erythematosus;
KW  transplant; atherosclerosis; organ damage; immunosuppressant.
XX

```

```

OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 1
FT Misc-difference 1 /note= "D-form residue"
FT Misc-difference 3 /note= "D-form residue"
XX
XX WO9627386-A1.
XX
XX 12-SEP-1996.
XX
XX 05-MAR-1996; 96WO-US03112.
XX
XX 12-SEP-1995; 95US-0527056.
XX
XX 06-MAR-1995; 95US-0400983.
XX
XX 07-JUN-1995; 95US-0484262.
XX
XX (HOUG-) Houghten PHARM INC.
XX
XX Andablibl A, Basu A, Fagan P, Giltren BE, Houghten RA;
XX Loullis CC, Omholt P, Suto MJ, Tuttle RR, Weber PA;
XX
XX WPI: 1996-425217/42.
XX
XX
XX Cytokine regulatory agents modified at the amino or carboxy terminus
XX - for controlling e.g. diabetes, obesity, septic shock, side
XX effects of cancer therapy
XX
XX
XX Claim 14; Page 76; 90pp; English.
XX
XX The sequences given in AA00266-72 represent cytokine regulatory
XX peptides which are modified at the amino or carboxy terminus. These
XX peptides are used to enhance or restrain cytokine activity and to treat
XX e.g. disease deconditioning, IL-10 activity diseases mediated by nitric
XX oxide and cytokines, adverse drug reactions, obesity, septic shock and
XX adverse side effects due to cancer chemotherapy or occurring as in
XX response to organ transplantation, immune, inflammatory and healing
XX process disorders, pain, cachexia, adult respiratory distress syndrome
XX (ARDS), autoimmune diseases esp. allergic reactions or anaphylaxis,
XX arthritis, inflammatory bowel disease, diabetes, glomerulonephritis,
XX systemic lupus erythematosus, transplant, atherosclerosis and parasitic
XX mediated immune dysfunctions such as charged disease, esp. organ damage
XX caused by ischemia reperfusion or immunosuppressant partic. cyclosporin.
XX The peptides also act to increase the oxygen consumption of a subject.
XX
XX
XX Sequence 3 AA:
XX
XX
XX Query Match 100.0%; Score 16; DB 17; Length 3;
XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
XX Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RW 2
XX | |
XX DB 2 RW 3
XX
XX
XX RESULT 7
XX ID AAR88899 standard; peptide; 3 AA.
XX
XX AAR88899;
XX
XX 29-OCT-1996 (first entry)
XX
XX Small synthetic antibiotic peptide for treating fungal infection.
XX
XX Antibiotic; antifungal; plant infection; horticultural; pesticide;
XX growth inhibition; Fusarium; Rhizoctonia; Ceratocystis; Pythium;
XX Mycosphaerella; Candida; fungus.
XX
XX Synthetic.
XX

```

```

FH Key Location/Qualifiers
FT Misc-difference 1..3
FT Misc-difference 1 /note= "at least one amino acid is pref. in D form"
XX
XX WO9608264-A1.
XX
XX 21-MAR-1996.
XX
XX 13-SEP-1995; 95WO-US11724.
XX
XX 13-SEP-1994; 94US-0305768.
XX
XX (CERE-) CERES TECHNOLOGIES INC.
XX
XX Edwards DL;
XX
XX WPI: 1996-179719/18.
XX
XX
XX New tri- to hexa-peptide antibiotics - used partic. for inhibiting
XX fungal growth in plants and plant prods. and for treating fungal
XX infections
XX
XX Claim 1; Page 27; 52pp; English.
XX
XX AAR8873-R888903 are antifungal peptides used for inhibiting the growth
XX of fungi species Fusarium, Rhizoctonia, Ceratocystis, Pythium,
XX Mycosphaerella and Candida. The peptides inhibit fungal growth in
XX agricultural and horticultural crops, they are partic. useful in
XX treating fungally damaged seeds, seedlings and trees. They have a
XX high specificity to the target fungi and a low toxicity and they
XX control fungal persistence in the environment. The peptides are also
XX used to treat pathogen infections such as yeast infections in animals
XX and man.
XX
XX N.B. Sequences given are taken from the disclosure of the
XX specification, those given in the SEQ ID listing correspond to the
XX sequences given but in the reverse order e.g. AAR8873 is given as
XX FRXXX (as it is given in the disclosure), but the same sequence is
XX referred to as SEQ ID number 1 which appears as XXXXR in the SEQ ID
XX listing.
XX
XX
XX Sequence 3 AA:
XX
XX
XX Query Match 100.0%; Score 16; DB 17; Length 3;
XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
XX Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 RW 2
XX | |
XX DB 2 RW 3
XX
XX
XX RESULT 8
XX ID AAR98551 standard; peptide; 3 AA.
XX
XX AAR98551;
XX
XX 12-NOV-1996 (first entry)
XX
XX Peptide for anti-ulcer agent.
XX
XX anti-ulcer agent; low toxicity; stable; heat-resistant.
XX
XX Synthetic.
XX
XX JP08143468-A.
XX
XX 04-JUN-1996.
XX
XX 17-NOV-1994; 94JP-0283869.
XX
XX 17-NOV-1994; 94JP-0283869.
XX

```

PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI; 1996-318857/32.
 XX
 PT Anti-ulcer agent contg. peptide - has low toxicity, is
 XX heat-resistant and water-soluble
 PS Claim 1; Page 10; 11pp; Japanese.
 XX
 CC AAR98531-54 are peptides used in an anti-ulcer agent. The agent is low
 CC in toxicity, is heat-resistant and stable in aqueous soln.. It can be
 CC administered orally and be produced in large amounts.
 XX
 SQ Sequence 3 AA;
 Query Match 100.0%; Score 16; DB 17; Length 3;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 DB 1 RW 2

RESULT 9
 AAR90605
 ID AAR90605 standard; peptide; 3 AA.
 XX
 AC AAR90605;
 XX
 DT 10-JUL-1996 (first entry)
 XX
 DE Lactoferrin derived peptide #21.
 XX
 KM Lactoferrin; antitumour; therapy; tumour; parenteral administration;
 KM thermostable; cytotoxic; antibacterial.
 XX
 OS Synthetic.
 XX
 PN JP07309771-A.
 XX
 PD 28-NOV-1995.
 XX
 PF 17-MAY-1994; 94JP-0103109.
 XX
 PR 17-MAY-1994; 94JP-0103109.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI; 1996-045317/05.
 XX
 PT Antitumour agent, derived from lactoferrin, for parenteral
 PT administration - has few side effects and is thermally stable and
 PT water soluble
 PS Claim 1; Page 8; 10pp; Japanese.
 XX
 CC AAR90585-R90613 represent lactoferrin derived peptides. These sequences
 CC can be used as antitumour agents for parenteral administration. The
 CC sequences are thermally stable, water soluble and stable in water.
 CC These peptide sequences are only cytotoxic to tumour cells.
 CC Administration of these sequences results in few side effects. No
 CC antiseptic is required for administration due to the antibacterial action
 CC of the peptide. Drugs made from these peptides can be rapidly
 CC metabolised.
 XX
 SQ Sequence 3 AA;
 Query Match 100.0%; Score 16; DB 17; Length 3;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2

DB 1 RW 2
 II
 1 RW 2

RESULT 10
 AAW56234
 ID AAW56234 standard; peptide; 3 AA.
 XX
 AC AAW56234;
 XX
 DT 20-JUL-1998 (first entry)
 XX
 DE Anti-inflammatory tripeptide.
 XX
 KM Anti-inflammatory; macrophage inhibitory activity; fibronectin;
 KM T-cell inhibitory activity; adherence; extracellular matrix;
 KM up-regulation; fas receptor expression; inflammation.
 XX
 OS Synthetic.
 XX
 PN WO9809985-A2.
 XX
 PD 12-MAR-1998.
 XX
 PE 03-SEP-1997; 97WO-IL00295.
 XX
 PR 28-MAY-1997; 97US-0864301.
 PR 03-SEP-1996; 96US-0025376.
 PR 20-NOV-1996; 96US-0753141.
 XX
 PA (YEDA) YEDA RES & DEV CO LTD.
 XX
 PI Beserman P, Eisenbachschwartz M, Hirschberg DL;
 DR WPI; 1998-193550/17.
 XX
 PT Anti-inflammatory peptides and derivatives - used for treating, e.g.
 PT arthritis, ulcerative colitis, auto-immune disease, allergy asthma,
 PT shock, HIV infection, transplant rejection or Alzheimer's disease
 XX
 PS Claim 7; Page 35; 42pp; English.
 XX
 CC AAW56171-248 represent anti-inflammatory tripeptides of the invention.
 CC They are derived from the formulae:
 CC Xaa-Glu-Arg, Arg-Glu-Xaa, Xaa-Arg-Glu, or Glu-arg-Xaa, where
 CC Xaa = any amino acid residue.
 CC Cyclic derivatives of the peptides also function as anti-inflammatory
 CC agents. The peptides can be covalently linked to one another either
 CC directly or through a spacer. The peptides and their derivatives have
 CC macrophage inhibitory and T-cell inhibitory activity and thus,
 CC anti-inflammatory activity. The peptides and compositions have
 CC anti-immune activity, i.e. inhibitory effects against a cellular and
 CC humoral immune response, including a response not associated with
 CC inflammation. The peptides also inhibit the ability of macrophages and
 CC T-cells to adhere to extracellular matrix components and fibronectin, as
 CC well as up-regulated fas receptor expression in T-cells. They can be
 CC used to inhibit unwanted immune reaction and inflammation.
 XX
 SQ Sequence 3 AA;
 Query Match 100.0%; Score 16; DB 19; Length 3;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 DB 2 RW 3

RESULT 11
 AAW52449
 ID AAW52449 standard; peptide; 3 AA.
 XX

AC AAW52449;
 XX
 DT 01-JUL-1998 (first entry)
 XX
 DE Loop region used in cyclic peptide of the invention.
 XX
 KM Loop region: cyclic peptide; antimicrobial; disinfectant; therapy;
 KM preservative; amphipathic anti-parallel beta-sheet region; plant disease.
 XX
 OS Synthetic.
 PN WO9803192-A1.
 XX
 PD 29-JAN-1998.
 XX
 PF 23-JUL-1997; 97WO-US12974.
 XX
 PR 24-JUL-1996; 96US-0685589.
 XX
 PA (INTR-) INTRADIOTICS PHARM INC.
 XX
 PI Chang C, Chen J, Gu L;
 XX
 DR WPI: 1998-120472/11.
 XX
 PT New cyclic peptide(s) with antimicrobial activity - contain
 PT amphipathic beta-sheet, loop and beta-turn regions, have better
 PT activity, bioavailability and protease resistance than linear
 PT analogues
 XX
 PS Claim 4: Page 151; 160pp; English.
 XX
 CC This sequence represents a loop region used in a peptide of the
 CC invention. The peptides are cyclic peptides (I), which have: (a) an
 CC amphipathic anti-parallel beta-sheet region (SR), a loop region (LR) and
 CC a beta-turn region (TR); (b) a net positive charge at physiological pH;
 CC and (c) at least one basic amino acid (aa) in LR or TR. (I) are broad
 CC spectrum antimicrobials, specifically for use against E. coli,
 CC pseudomonas aeruginosa, methicillin-resistant staphylococcus aureus
 CC (MRSA), vancomycin-resistant Enterococcus faecium and
 CC penicillin-resistant Streptococcus pneumoniae. More generally they are
 CC active against Gram-positive or -negative bacteria, fungi, yeast and
 CC protozoa. Apart from clinical uses, (I) are also used as disinfectants
 CC and preservatives for medical equipment, foods, cosmetics etc., also for
 CC treatment of plant diseases. Compared with non-cyclised analogues (I.e.
 CC lachyplesin and protegrin type peptides), (I) and are more effective,
 CC with better bioavailability and/or serum half-life (increased resistance
 CC to proteolysis). They are more suitable for oral administration, can be
 CC used at lower doses and are unlikely to induce development of resistant
 CC strains.
 CC
 SQ Sequence 3 AA;
 XX
 XX
 Query Match 100.0%; Score 16; DB 19; Length 3;
 Best Local Similarity 100.0%; Pred. NO. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 DB 2 RW 3
 XX
 XX
 RESULT 12
 AAW41286
 ID AAW41286 standard; peptide; 3 AA.
 XX
 AC AAW41286;
 XX
 DT 20-MAY-1998 (first entry)
 XX
 DE Apoptosis inducer peptide.
 XX
 KM Apoptosis inducer; hydrolysed lactoferrin.

XX
 OS Synthetic.
 XX
 PN JP10045618-A.
 XX
 PD 17-FEB-1998.
 XX
 PF 26-JUL-1996; 96JP-0198196.
 XX
 PR 26-JUL-1996; 96JP-0198196.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI: 1998-189187/17.
 XX
 PT New inducer(s) of apoptosis - comprise active parts of peptide(s)
 PT derived from hydrolysis of lactoferrin
 XX
 PS Claim 3; Page 9; 11pp; Japanese.
 XX
 CC This sequence represents an apoptosis inducer peptide of the invention.
 CC The apoptosis inducers comprising active parts of peptides derived from
 CC hydrolysed lactoferrin. The peptides can be used to prepare therapeutic
 CC compositions in the form of tablets, capsules or injections. The inducers
 CC are safe and do not cause adverse reactions.
 CC
 SQ Sequence 3 AA;
 XX
 XX
 Query Match 100.0%; Score 16; DB 19; Length 3;
 Best Local Similarity 100.0%; Pred. NO. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 DB 1 RW 2
 XX
 XX
 RESULT 13
 AAR07102
 ID AAR07102 standard; protein; 4 AA.
 XX
 AC AAR07102;
 XX
 DT 23-JAN-1991 (first entry)
 XX
 DE Melanocyte-stimulating hormone inhibitor #7.
 XX
 KM melanocyte-stimulating hormone (MSH) inhibitors; freckles;
 KM epidermal chloasmatia; melanoma; whitening agent.
 XX
 OS Synthetic.
 XX
 PN EP389950-A.
 XX
 PD 03-OCT-1990.
 XX
 PF 21-MAR-1990; 90EP-0105354.
 XX
 PR 13-APR-1989; 89JP-0093643.
 XX
 PR 23-MAR-1989; 89JP-0071215.
 XX
 PA (LIOY) LION CORP.
 XX
 PI Takeuchi T, Sato C, Oba K, Sugiyama K;
 XX
 DR WPI: 1990-298939/40.
 XX
 PT New peptide(s) - useful as melanocyte-stimulating hormone
 PT inhibitors, in the treatment of symptoms of chloasmatia and
 PT freckles.
 XX
 PS Claim 1; Page 21; 22pp; English.

CC This peptide comprises the essential amino acids for MSH inhibitory
CC activity. Two other motifs have been identified and peptides
CC containing any one of the 3 sequences can be used as MSH
CC inhibitors. The peptides have an affinity for melanocyte receptors
CC and antagonise MSH. They can be administered topically, orally or
CC parenterally.
CC See also AAR07096-R07101 and AAR07103-R07104.
XX

SQ Sequence 4 AA;

Query Match

Best Local Similarity 100.0%; Score 16; DB 11; Length 4;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
11
DB 3 RW 4

RESULT 14

AAR42570

ID AAR42570 standard; peptide; 4 AA.

XX AAR42570;

DT 22-JUN-1994 (first entry)

DE Peptide corresponding to pseudo-substrate region of zeta-PKC.

KW zeta-protein kinase C inhibitor; zeta-PKC; pseudosubstrate; tumour;
KM hyperproliferative disorders; psoriasis; viral infection; HIV.

XX Synthetic.

OS MO9320101-A.

PN 14-OCT-1993.

PD 02-APR-1993; 93WO-EP00816.

PF 06-APR-1992; 92EP-0500034.

PR (GLAX) GLAXO SA.

PA DIAZ-MECO CONDE MT, MOSCAR GUILLEN J;

XX WPI; 1993-336831/42.

DR Peptide(s) corresp. to the pseudo-substrate region of zeta-PKC -
PT used for treatment of tumours, hyper-proliferative disorders and
PT viral infections

PS Claim 4; Page 43; 57pp; English.

XX The main claim refers to new peptides of formula X-Ala-Arg-Arg-J in
CC which X is H or one or more amino acids and J is OH or one or more
CC amino acids, the peptides containing a total of 3 to 15 amino acids.
CC The present peptide is a specifically claimed example of these new
CC peptides.

CC The peptides are specific inhibitors of protein kinase C isotype
CC zeta, i.e. any subspecies of PKC which contains the specific
CC autoinhibitory pseudosubstrate domain RRGARRWRK (Acc. No. AAR42573).
CC This domain has been found to be perfectly conserved in zeta-PKC
CC variants isolated from a number of different sources, including rat
CC brain. The peptides are usefully therapeutically for treating
CC conditions where the underlying aetiology is associated with
CC zeta-PKC, including tumours, hyperproliferative disorders (e.g.
CC psoriasis) and viral infections (e.g. HIV).

SQ Sequence 4 AA;

Query Match 100.0%; Score 16; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RW 2
11
DB 3 RW 4

RESULT 15

AAR41642

ID AAR41642 standard; peptide; 4 AA.

XX AAR41642;

DT 10-MAR-1994 (first entry)

DE Internalisation signal #7.

KW Internalisation signal; core; modulation; receptor; transport; ligand;
KM cytoplasmic tail; endocytosis.

XX Synthetic.

OS MO9318185-A.

PN 16-SEP-1993.

PD 01-MAR-1993; 93WO-US01669.

PF 03-MAR-1992; 92US-0844852.

PR (SALK) SALK INST BIOLOGICAL STUDIES.
PA (SCRI) SCRIPPS RES INST.

XX Collawn JF, Kuhn LA, Tainer JA, Trowbridge IS;

XX WPI; 1993-303496/38.

DR Modulating receptor mediated transport of ligand into cell - by
PT introducing heterologous internalisation signal into cell

PS Claim 16; Page 49; 60pp; English.

XX The sequences given in AAR41636-57 represent the cores of
CC internalisation signals which were used in the method of the invention
CC for modulating receptor mediated transport of a ligand into a cell.
CC These sequences are derived from the cytoplasmic tails of surface
CC receptors. These amino acid internalisation signals have a tight turn
CC structure. The introduction of one of these sequences into a receptor
CC within a cell, modulates the transport of ligand into a cell having a
CC surface receptor reactive with that ligand. This modulation can cause an
CC increase or a decrease in endocytosis, depending on the choice of
CC internalisation signal.

SQ Sequence 4 AA;

Query Match

Best Local Similarity 100.0%; Score 16; DB 14; Length 4;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
11
DB 3 RW 4

RESULT 16

AAR48521

ID AAR48521 standard; peptide; 4 AA.

XX AAR48521;

DT 10-AUG-1994 (first entry)

DE Lactoferrin derived peptide #15.

XX Decomposition; lactoferrin; digestion; enzyme; pepsin; trypsin;
 KW antioxidant; oxidation; inhibitor; vitamin E; ascorbic acid;
 KW vitamin A; beta-carotene; superoxide dismutase; coenzyme Q;
 KW lipid oxidation; foodstuff; drugs; health food; toiletries; cosmetics.
 XX
 OS Bos taurus.
 XX
 PN WO9403555-A.
 XX
 PD 17-FEB-1994.
 XX
 PE 04-AUG-1993; 93WO-JP01090.
 XX
 PR 07-AUG-1992; 92JP-0211335.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 PI Bellamy WR, Fukawatari Y, Kawase K, Shimamura S,
 PI Takase M, Tokiday, Tomita M, Wakabayashi H, Yamauchi K;
 XX
 DR WPI; 1994-065650/08.
 XX
 PT Antioxidant peptide lactoferrin decomposition product - prevents
 PT oxidation of lipid(s) in foodstuffs and drugs without affecting
 PT their taste
 XX
 PS Claim 3; Page 31; 47pp; Japanese.
 XX
 CC The sequences given in AAR48507-37 are peptides derived by the
 CC decomposition of lactoferrin, pref. by digestion with an enzyme, eg.
 CC pepsin or trypsin. These peptides may be used in an antioxidant
 CC composition which may also contain an oxidation inhibitor such as
 CC vitamin E, ascorbic acid, vitamin A, beta-carotene, superoxide
 CC dismutase or coenzyme Q. The antioxidant prevents lipid oxidation
 CC in foodstuffs, drugs, health foods, toiletries and cosmetics.
 XX
 SQ Sequence 4 AA;
 Query Match 100.0%; Score 16; DB 15; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 II
 DB 2 RW 3
 RESULT 17
 AAR48526
 ID AAR48526 standard; peptide; 4 AA.
 XX
 AC AAR48526;
 XX
 DT 10-AUG-1994 (first entry)
 XX
 DE Lactoferrin derived peptide #20.
 XX
 KW Decomposition; lactoferrin; digestion; enzyme; pepsin; trypsin;
 KW antioxidant; oxidation; inhibitor; vitamin E; ascorbic acid;
 KW vitamin A; beta-carotene; superoxide dismutase; coenzyme Q;
 KW lipid oxidation; foodstuff; drugs; health food; toiletries; cosmetics.
 XX
 OS Bos taurus.
 XX
 PN WO9403555-A.
 XX
 PD 17-FEB-1994.
 XX
 PE 04-AUG-1993; 93WO-JP01090.
 XX
 PR 07-AUG-1992; 92JP-0211335.
 XX

PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 PI Bellamy WR, Fukawatari Y, Kawase K, Shimamura S;
 PI Takase M, Tokiday, Tomita M, Wakabayashi H, Yamauchi K;
 XX
 DR WPI; 1994-065650/08.
 XX
 PT Antioxidant peptide lactoferrin decomposition product - prevents
 PT oxidation of lipid(s) in foodstuffs and drugs without affecting
 PT their taste
 XX
 PS Claim 3; Page 33; 47pp; Japanese.
 XX
 CC The sequences given in AAR48507-37 are peptides derived by the
 CC decomposition of lactoferrin, pref. by digestion with an enzyme, eg.
 CC pepsin or trypsin. These peptides may be used in an antioxidant
 CC composition which may also contain an oxidation inhibitor such as
 CC vitamin E, ascorbic acid, vitamin A, beta-carotene, superoxide
 CC dismutase or coenzyme Q. The antioxidant prevents lipid oxidation
 CC in foodstuffs, drugs, health foods, toiletries and cosmetics.
 XX
 SQ Sequence 4 AA;
 Query Match 100.0%; Score 16; DB 15; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 II
 DB 2 RW 3
 RESULT 18
 AAR57452
 ID AAR57452 standard; Protein; 4 AA.
 XX
 AC AAR57452;
 XX
 DT 28-FEB-1995 (first entry)
 XX
 DE Lactoferrin derived peptide #15.
 XX
 KW Lactoferrin; chemical; enzymatic; hydrolysis; antimicrobial;
 KW antiseptic; ischemic disease.
 XX
 OS Mus musculus.
 XX
 PN JP06172200-A.
 XX
 PD 21-JUN-1994.
 XX
 PE 08-DEC-1992; 92JP-0327738.
 XX
 PR 08-DEC-1992; 92JP-0327738.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI; 1994-238662/29.
 XX
 PT Brain protectant for preventing ischemic diseases without side
 PT effects - comprising 31 specified peptide(s), prepd. by
 PT lactoferrin hydrolysis
 XX
 PS Disclosure; Page 8; 11pp; Japanese.
 XX
 CC The sequences given in AAR57438-68 represent fragments of lactoferrin
 CC which were derived from the full length protein by chemical or enzyme
 CC hydrolysis. These peptides have brain protecting properties, as
 CC well as anti-microbial activity. Compositions containing these
 CC peptides may be prepared with out the addition of anesthetics, and
 CC may be administered at doses of at least 10 mg for parenteral,
 CC administration and 100 mg for oral administration. These peptides
 CC are stable, heat resistant, water soluble and may be used for the


```

CC prevention of ischaemic diseases without side effects.
XX
SQ Sequence 4 AA;
Query Match 100.0%; Score 16; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RW 2
    ||
    ||
DB 2 RW 3

RESULT 19
AAR57457
ID AAR57457 standard; Protein; 4 AA.
AC AAR57457;
DT 28-FEB-1995 (first entry)
DE Lactoferrin derived peptide #20.
XX
XX Lactoferrin; chemical; enzymatic; hydrolysis; antimicrobial;
KW antiseptic; ischaemic disease.
XX
XX Mus musculus.
OS
PN JP06172200-A.
PD 21-JUN-1994.
XX
XX 08-DEC-1992; 92JP-0327738.
PF
XX PR 08-DEC-1992; 92JP-0327738.
XX
XX (MORG ) MORINAGA MILK IND CO LTD.
PA
XX WPI; 1994-238662/29.
DR
XX Brain protectant for preventing ischaemic diseases without side
PT effects - comprising 31 specified peptide(s), prepd. by
PS Lactoferrin hydrolysis
XX
XX Disclosure: Page 9; 11pp; Japanese.
PS
XX The sequences given in AAR57438-68 represent fragments of lactoferrin
CC which were derived from the full length protein by chemical or enzyme
CC hydrolysis. These peptides have brain protecting properties, as
CC well as anti-microbial activity. Compositions containing these
CC peptides may be prepared with out the addition of antiseptics, and
CC may be administered at doses of at least 10 mg for parenteral
CC administration and 100 mg for oral administration. These peptides
CC are stable, heat resistant, water soluble and may be used for the
CC prevention of ischaemic diseases without side effects.
XX
SQ Sequence 4 AA;
Query Match 100.0%; Score 16; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RW 2
    ||
    ||
DB 2 RW 3

RESULT 20
AAR57897
ID AAR57897 standard; Protein; 4 AA.
AC AAR57897;
XX

```

```

DT 29-MAR-1995 (first entry)
XX
XX Integrin binding site #1.
DE
XX Binding site; CDR; complementarily determining region; immunoglobulin;
KW heavy; light; primer extension; PCR; amplify; fibronectin; vitronectin;
KW RGD-dependent; Integrin ligand; von Willebrand factor; EBV; gp350/220;
KW envelope glycoprotein; HIV; gp120; reovirus; hemagglutinin; insulin;
KW cellular receptor; CR2; CD4; hormone; thyroid stimulating hormone; TSH;
KW transferrin; apolipoprotein; apo E; apo AI; MHC; class I; class II;
KW non-RGD-dependent; vitronectin receptor; alpha-v, beta-3; modulation;
KW anti-gp11b/IIb; monoclonal antibody; Mab; platelet adhesion; cancer;
KW coagulation; inflammation; anti-vitronectin; tumour cell adhesion;
KW migration.
XX
XX Synthetic.
OS
PN WO9418221-A.
PD 18-AUG-1994.
XX
XX 02-FEB-1994; 94WO-US01258.
PF
XX PR 02-FEB-1993; 93US-0012566.
XX PR 28-JUN-1993; 93US-0084542.
XX
XX (SCTR ) SCRIPPS RES INST.
PA
XX Barbas CF, Lerner RA;
PI
XX WPI; 1994-279675/34.
DR
XX
XX Production of binding sites within CDR regions of immunoglobulins
PT - displayed on the surface of filamentous phage particles, for
PT inhibiting platelet aggregation and vitronectin binding
XX
XX Example 5; Page 145; 207pp; English.
PS
XX The sequences given in AAR57897-900 represents non-RGD integrin ligand
CC binding sites. These binding site peptides were used in the method
CC of the invention for producing a polypeptide having a binding site
CC capable of binding a preselcted agent. Nucleotide sequences encoding
CC these binding site peptides were introduced into a CDR region of a
CC nucleic acid encoding an immunoglobulin heavy (H) or light (L) chain,
CC by amplifying the CDR region by primer extension. Preferred binding
CC sites are derived from the RGD-dependent integrin ligands, eg.
CC fibronectin, vitronectin, von Willebrand factor, from the envelope
CC glycoprotein from viruses such as HIV gp120, EBV gp350/220, reovirus
CC hemagglutinin, from cellular receptors such as CR2 or CD4, from protein
CC hormones such as thyroid stimulating hormone (TSH), insulin,
CC transferrin, from apolipoproteins such as apo E and apo AI, from
CC immunoglobulin CDRs and from MHC class I or II proteins. Non-RGD-
CC dependent integrin binding sites were selected for the affinity to
CC bind vitronectin receptor alpha-v, beta-3. An anti-gp11b/IIa
CC monoclonal antibody (Mab) produced in this way can be used to modulate
CC platelet adhesion in the treatment of coagulation and some inflammatory
CC responses. An anti-vitronectin Mab can be used in the treatment of
CC cancer by blocking tumour cell adhesion and migration.
XX
SQ Sequence 4 AA;
Query Match 100.0%; Score 16; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 RW 2
    ||
    ||
DB 1 RW 2

RESULT 21
AAR81695
ID AAR81695 standard; peptide; 4 AA.

```

XX AAR81695;
 AC 06-JUL-1999 (first entry)
 DT XX
 DE Analogue of alpha-MSH fragment, conjugated with thioctic acid.
 XX
 KW Alpha-melanocyte stimulating hormone; MSH; thioctic acid; lipolic;
 KW antiallergic; antiinflammatory; cosmetic; skin tanning accelerator.
 XX Synthetic.
 OS
 XX
 FH Key
 FT Modified-site 1 Location/Qualifiers
 FT /note= "The peptide is conjugated with lipolic acid
 FT (i.e. thioctic acid) or with N-lipoyl-lysine"
 FT Modified-site 2
 FT /note= "D-homo-Phe"
 FT Modified-site 4
 FT /note= "Trp-NH2"
 FT
 FT
 PN WO9508564-A1.
 XX
 PD 30-MAR-1995.
 XX
 PF 22-SEP-1994; 94WO-FR01108.
 XX
 PR 22-SEP-1993; 93FR-0011281.
 XX
 PA (EUBI-) INST EURO BIOLOGIE CELLULAIRE.
 XX
 PI Dussourd d'Hinterland L, Pinel AM;
 XX
 DR WPI; 1995-139550/18.
 XX
 XX
 PT New lipoyl derivs. of melanocyte stimulating hormone fragments -
 PT useful as antiallergic, antiinflammatory and skin-tanning agents
 XX
 PS Claim 5; Pages 33, 34; 42pp; French.
 XX
 CC New peptide derivatives are disclosed which comprises a sequence of
 CC at least 4 amino acids from alpha-MSH (melanocyte stimulating hormone)
 CC linked to thioctic (lipolic) acid or a derivative of this acid. The
 CC amino acids are in natural or non-natural form and preferably include
 CC the sequence His-Phe-Ary in which the Phe residue is in the form of
 CC homophe or p-fluorophe. These compounds are useful for pharmaceutical
 CC purposes, especially as antiallergic and antiinflammatory agents, and
 CC for cosmetic purposes, e.g. as skin tanning accelerators.
 XX
 SQ Sequence 4 AA;
 OY Query Match 100.0%; Score 16; DB 16; Length 4;
 DB Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 II
 DB 3 RW 4

RESULT 22
 AAR84694
 ID AAR84694 standard; peptide; 4 AA.
 XX
 AC AAR84694;
 XX
 DT 13-JUN-1996 (first entry)
 XX
 DE Bovine lactoferrin derived angina pectoris treating peptide.
 XX
 KW Bovine lactoferrin; angina pectoris; treatment; low toxicity;
 KW no side effects; heat resistance; water solubility; stability;
 KW aqueous solution; preservative free.

XX OS Bos taurus.
 XX JP07278011-A.
 PN
 XX
 PD 24-OCT-1995.
 XX
 PF 01-APR-1994; 94JP-0085243.
 XX
 PR 01-APR-1994; 94JP-0085243.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI; 1995-400916/51.
 XX
 PT Peptide for treatment of angina pectoris - has low toxicity and is
 PT heat resistant and water soluble
 XX
 PS Claim 1; Page 10; 12pp; Japanese.
 XX
 CC The present peptide is a bovine lactoferrin derived, angina
 CC pectoris treatative agent. It has low toxicity and side effects,
 CC is heat resistant, water soluble and stable in an aq. soln.. It
 CC also requires no preservative.
 XX
 SQ Sequence 4 AA;
 OY Query Match 100.0%; Score 16; DB 16; Length 4;
 DB Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 II
 DB 2 RW 3

RESULT 23
 AAR84689
 ID AAR84689 standard; peptide; 4 AA.
 XX
 AC AAR84689;
 XX
 DT 13-JUN-1996 (first entry)
 XX
 DE Bovine lactoferrin derived angina pectoris treating peptide.
 XX
 KW Bovine lactoferrin; angina pectoris; treatment; low toxicity;
 KW no side effects; heat resistance; water solubility; stability;
 KW aqueous solution; preservative free.
 XX
 OS Bos taurus.
 XX
 PN JP07278011-A.
 XX
 PD 24-OCT-1995.
 XX
 PF 01-APR-1994; 94JP-0085243.
 XX
 PR 01-APR-1994; 94JP-0085243.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 XX
 DR WPI; 1995-400916/51.
 XX
 PT Peptide for treatment of angina pectoris - has low toxicity and is
 PT heat resistant and water soluble
 XX
 PS Claim 1; Page 9; 12pp; Japanese.
 XX
 CC The present peptide is a bovine lactoferrin derived, angina
 CC pectoris treatative agent. It has low toxicity and side effects,
 CC is heat resistant, water soluble and stable in an aq. soln.. It
 CC also requires no preservative.

```

XX SQ Sequence 4 AA:
Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
   ||
DB 2 RW 3

RESULT 24
AAR75601
ID AAR75601 standard; peptide; 4 AA.
XX
AC AAR75601;
XX
DT 06-MAR-1996 (first entry)
XX
DE gp120 binding Fab VH CDR3 residues 96-99 #6.
XX
KW Human; Fab; variable chain; heavy; light; region: VH; VL; HIV; gp120;
KM 3b1; 3b3; 3b4; 3b9; MT4; humanised; monoclonal antibody; MAb;
KW immunoreaction; neutralisation; passive immunotherapy.
XX
OS Synthetic.
XX
PN WO9511317-A1.
XX
PD 27-APR-1995.
XX
PF 19-OCT-1994; 94WO-US11907.
XX
PR 19-SEP-1994; 94US-0308841.
PR 19-OCT-1993; 93US-0139409.
PR 26-APR-1994; 94US-0233619.
XX
PA (SCRI ) SCRIPPS RES INST.
XX
PI Barbas CF, Burton DR, Lerner RA;
XX
DR WPI; 1995-170235/22.
XX
PT Synthetic human neutralising monoclonal antibodies to human
PT immunodeficiency virus - used for diagnosis and immuno:therapy of
PT HIV-induced disease
XX
PS Example 2; Fig 5; 249pp; English.
XX
The sequences given in AAR75576-603 represent complementarity
determining region 3 (CDR3) from various mutagenised human Fab's which
comprise a variable chain heavy regions (VH), which bind to HIV gp120.
The Fab's are based on the Fab MT4 and have the same amino acid
composition as MT4 but have randomised amino acids in the entire CDR1 and
in four of the 18 amino acid residues in CDR3 (see also AAR75575-94).
These Fab's are used in the production of a human monoclonal antibody
(MAb) which is capable of immunoreacting with, and neutralising HIV. The
MAb's are capable of reducing HIV infectivity titre in an in vitro virus
infectivity assay by 50% at a concentration of <100 ng of antibody per
ml. They can be used to provide passive immunotherapy to HIV in a human.
They neutralise HIV more effectively than antibodies selected from
non-randomised combinatorial libraries.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
   ||
DB 3 RW 4

```

```

RESULT 25
AAR75603
ID AAR75603 standard; peptide; 4 AA.
XX
AC AAR75603;
XX
DT 06-MAR-1996 (first entry)
XX
DE gp120 binding Fab VH CDR3 residues 96-99 #8.
XX
KW Human; Fab; variable chain; heavy; light; region: VH; VL; HIV; gp120;
KM 3b1; 3b3; 3b4; 3b9; MT4; humanised; monoclonal antibody; MAb;
KW immunoreaction; neutralisation; passive immunotherapy.
XX
OS Synthetic.
XX
PN WO9511317-A1.
XX
PD 27-APR-1995.
XX
PF 19-OCT-1994; 94WO-US11907.
XX
PR 19-SEP-1994; 94US-0308841.
PR 19-OCT-1993; 93US-0139409.
PR 26-APR-1994; 94US-0233619.
XX
PA (SCRI ) SCRIPPS RES INST.
XX
PI Barbas CF, Burton DR, Lerner RA;
XX
DR WPI; 1995-170235/22.
XX
PT Synthetic human neutralising monoclonal antibodies to human
PT immunodeficiency virus - used for diagnosis and immuno:therapy of
PT HIV-induced disease
XX
PS Example 2; Fig 5; 249pp; English.
XX
The sequences given in AAR75576-603 represent complementarity
determining region 3 (CDR3) from various mutagenised human Fab's which
comprise a variable chain heavy regions (VH), which bind to HIV gp120.
The Fab's are based on the Fab MT4 and have the same amino acid
composition as MT4 but have randomised amino acids in the entire CDR1 and
in four of the 18 amino acid residues in CDR3 (see also AAR75575-94).
These Fab's are used in the production of a human monoclonal antibody
(MAb) which is capable of immunoreacting with, and neutralising HIV. The
MAb's are capable of reducing HIV infectivity titre in an in vitro virus
infectivity assay by 50% at a concentration of <100 ng of antibody per
ml. They can be used to provide passive immunotherapy to HIV in a human.
They neutralise HIV more effectively than antibodies selected from
non-randomised combinatorial libraries.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
   ||
DB 3 RW 4

RESULT 26
AAR87663
ID AAR87663 standard; peptide; 4 AA.
XX
AC AAR87663;
XX
DT 15-FEB-1996 (first entry)
XX

```

```

DE His-(D)Phe-Arg-(D)Trp or cyclo(His-(D)Phe-Arg-(D)Trp).
XX cytokine; interferon; interleukin; tumour necrosis factor; TNF;
KW restraining; cyclic.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1 /note= "this site is optionally alpha-N-acetylated;
FT /note= "alternatively, the C-terminal D-Trp may be
FT condensed onto this residue to give a
FT cyclic peptide"
FT
FT Misc-difference 2 /note= "D-form residue"
FT
FT Misc-difference 4 /note= "D-form residue; this residue is optionally
FT in amide form, or it may be condensed
FT onto the N-terminal His to form a cyclic
FT peptide"
FT
XX WO9513086-A1.
XX
XX 18-MAY-1995.
XX
XX 09-NOV-1994; 94WO-US12897.
XX
XX 12-NOV-1993; 93US-0151534.
XX
XX (HOUG-) HOUGHTEN PHARM INC.
XX
XX Gitten BE, Houghten RA, Loullis CC, Suto MJ, Tuttle RR;
XX
XX WPI; 1995-193901/25.
XX
XX Cytokine restraining peptides useful for treating inflammation,
XX cachexia and patho-immunogenic disease - do not cause total
XX immunosuppression and minimise damage to healthy tissue.
XX
XX Claims 24, 27; Page 33; 41pp; English.
XX
XX The patent discloses new cytokine restraining peptides and their amino-
XX saccharide conjugates. The peptides contain a core sequence of
XX His-(D)Phe-Arg-(D)Trp, and may be extended by up to 2 amino acids at
XX the N-terminal and by 1 amino acid at the C-terminal. The N-terminal may
XX be acetylated and the C-terminal can be in amide form, or the peptide
XX can be cyclic, with the C-terminal condensing onto the N-terminal.
XX The peptides can restrain activity due to elevated levels of
XX interleukins, interferons and tumour necrosis factors and thus control
XX immune and inflammatory responses. They are useful in the treatment of
XX inflammation, pain, cachexia, arthritis, inflammatory bowel disease and
XX systemic lupus erythematosus (SLE).
XX
XX The present sequence represents specific examples of the new peptides.
XX
XX Sequence 4 AA:
XX
XX Query Match 100.0%; Score 16; DB 16; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
XX Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RW 2
XX ||
XX DB 3 RW 4
XX
XX RESULT 27
XX AAR87659
XX ID AAR87659 standard; peptide: 4 AA.
XX
XX AC AAR87659;
XX
XX 14-FEB-1996 (first entry)
XX

```

```

DE His-(D)Phe-Arg-(D)Trp core peptide.
XX cytokine; interferon; interleukin; tumour necrosis factor; TNF;
KW restraining.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 2 /note= "D-form residue"
FT
FT Misc-difference 4 /note= "D-form residue"
FT
FT Misc-difference 2 /note= "D-form residue"
FT
XX WO9513086-A1.
XX
XX 18-MAY-1995.
XX
XX 09-NOV-1994; 94WO-US12897.
XX
XX 12-NOV-1993; 93US-0151534.
XX
XX (HOUG-) HOUGHTEN PHARM INC.
XX
XX Gitten BE, Houghten RA, Loullis CC, Suto MJ, Tuttle RR;
XX
XX WPI; 1995-193901/25.
XX
XX Cytokine restraining peptides useful for treating inflammation,
XX cachexia and patho-immunogenic disease - do not cause total
XX immunosuppression and minimise damage to healthy tissue.
XX
XX Claim 1; Page 29; 41pp; English.
XX
XX The patent discloses new cytokine restraining peptides and their amino-
XX saccharide conjugates. The peptides contain a core sequence of
XX His-(D)Phe-Arg-(D)Trp, and may be extended by up to 2 amino acids at
XX the N-terminal and by 1 amino acid at the C-terminal. The N-terminal may
XX be acetylated and the C-terminal can be in amide form, or the peptide
XX can be cyclic, with the C-terminal condensing onto the N-terminal.
XX The peptides can restrain activity due to elevated levels of
XX interleukins, interferons and tumour necrosis factors and thus control
XX immune and inflammatory responses. They are useful in the treatment of
XX inflammation, pain, cachexia, arthritis, inflammatory bowel disease and
XX systemic lupus erythematosus (SLE).
XX
XX The present sequence represents the core sequence described above.
XX
XX Sequence 4 AA:
XX
XX Query Match 100.0%; Score 16; DB 16; Length 4;
XX Best Local Similarity 100.0%; Pred. No. 7.8e+05;
XX Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 RW 2
XX ||
XX DB 3 RW 4
XX
XX RESULT 28
XX AAR79363
XX ID AAR79363 standard; peptide: 4 AA.
XX
XX AC AAR79363;
XX
XX 13-OCT-1995 (first entry)
XX
XX Mutant thrombospondin Type-1 repeat sequence peptide F414W.
XX
XX DE Thrombospondin type 1 repeat sequence; transforming growth factor-beta;
XX wound healing; fibrosis; endothelial cell proliferation.
XX
XX OS Synthetic.
XX
XX WO9505191-A.
XX

```

```

XX 23-FEB-1995.
PD
XX 12-AUG-1994; 94WO-US09193.
PF
XX 13-AUG-1993; 93US-0106120.
PR 04-MAY-1994; 94US-0238169.
XX
XX (UABR-) UAB RES FOUND.
XX
XX Kruttsch HC, Murphy-Ullrich JE, Roberts DD, Schultz-Cherry S;
PI WPI; 1995-098579/13.
XX
XX Stimulating or inhibiting transforming growth factor-beta by
PT contacting with thrombo-spondin or an activating enzyme - used
PT to enhance wound healing or prevent fibrosis
XX
XX Examples: Page 27; 67pp; English.
PS
XX The peptides (AAR79357-63) are mutated consensus type 1 repeat sequence
CC peptides (amino acids 412-473) of thrombospondin (sequence not given in
CC the specification) which cannot stimulate the conversion of transforming
CC growth factor-beta (TGF-b) from its latent to active form. This peptide
CC has a substitution of the Phe at pos. 414 for a Trp residue. Other
CC peptides (see AAR69766-90) contain this stimulatory or inhibitory
CC activity. The inhibitory peptides (AAR69780-90) can be used to prevent
CC fibrosis or block TGF-b mediated endothelial cell proliferation.
CC Peptides (see AAR69766-79) which stimulate the conversion of latent TGF-b
CC to active TGF-b can be used to enhance wound healing.
XX
XX Sequence 4 AA:
SQ
Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RW 2
    ||
    Db 2 RW 3
RESULT 29
AAR79759
ID AAR79759 standard; peptide; 4 AA.
XX
XX AAR79759;
AC
XX
XX 21-FEB-1996 (first entry)
DT
XX
XX Anti-parasitic lactoferrin hydrolysate derived peptide.
DE
XX
XX Anti-parasitic; lactoferrin; hydrolysate; non-toxic; aquatic animals;
KM cultured fish; shellfish.
XX
XX Homo sapiens.
OS
XX JP07145069-A.
PN
XX
XX 06-JUN-1995.
PD
XX 26-NOV-1993; 93JP-0296281.
PF
XX 26-NOV-1993; 93JP-0296281.
PR
XX (MORG ) MORINAGA MILK IND CO LTD.
PA
XX WPI; 1995-237144/31.
DR
XX
XX Drug containing lactoferrin or peptide(s) isolated from its
PT hydrolysates - for prevention or therapy of parasitic diseases in
PT aquatic animals esp. cultured fish and shellfish
XX

```

```

PS Claim 3; Page 10; 14pp; Japanese.
XX
XX AAR79746/60 and AAR80258/70 are non-toxic anti-parasitic peptides
CC derived from lactoferrin hydrolysates. Alone, or in combination
CC with lactoferrins and/or their hydrolysates, the peptides can be
CC used to treat or prevent infectious diseases caused by parasites
CC in aquatic animals, e.g. cultured fish and shellfish.
XX
XX Sequence 4 AA:
SQ
Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RW 2
    ||
    Db 2 RW 3
RESULT 30
AAR80260
ID AAR80260 standard; peptide; 4 AA.
XX
XX AAR80260;
AC
XX
XX 21-FEB-1996 (first entry)
DT
XX
XX Anti-parasitic lactoferrin hydrolysate derived peptide.
DE
XX
XX Anti-parasitic; lactoferrin; hydrolysate; non-toxic; aquatic animals;
KM cultured fish; shellfish.
XX
XX Homo sapiens.
OS
XX JP07145069-A.
PN
XX
XX 06-JUN-1995.
PD
XX 26-NOV-1993; 93JP-0296281.
PF
XX 26-NOV-1993; 93JP-0296281.
PR
XX (MORG ) MORINAGA MILK IND CO LTD.
PA
XX WPI; 1995-237144/31.
DR
XX
XX Drug containing lactoferrin or peptide(s) isolated from its
PT hydrolysates - for prevention or therapy of parasitic diseases in
PT aquatic animals esp. cultured fish and shellfish
XX
XX Claim 3; Page 11; 14pp; Japanese.
DE
XX
XX AAR79746/60 and AAR80258/70 are non-toxic anti-parasitic peptides
CC derived from lactoferrin hydrolysates. Alone, or in combination
CC with lactoferrins and/or their hydrolysates, the peptides can be
CC used to treat or prevent infectious diseases caused by parasites
CC in aquatic animals, e.g. cultured fish and shellfish.
XX
XX Sequence 4 AA:
SQ
Query Match 100.0%; Score 16; DB 16; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RW 2
    ||
    Db 2 RW 3
RESULT 31
AAW77478
ID AAW77478 standard; peptide; 4 AA.
XX

```


XX DE Cytokine regulatory peptide #6.
 XX
 KW Cytokine regulatory peptide; disuse deconditioning; IL-10;
 KW nitric oxide; adverse drug reaction; obesity; septic shock;
 KW cancer chemotherapy; organ transplant; cachexia; cyclosporin;
 KW adult respiratory distress syndrome; ARDS; autoimmune disease;
 KW allergic reaction; anaphylaxis; arthritis; inflammatory bowel disease;
 KW diabetes; glomerulonephritis; systemic lupus erythematosus; cyclic;
 KW transplant; atherosclerosis; organ damage; immunosuppressant.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 2 /note= "D-form residue"
 FT Modified-site 4 /note= "D-form residue"
 FT
 XX
 PN W09627386-A1.
 XX
 PD 12-SEP-1996.
 XX
 PF 05-MAR-1996; 96MO-US03112.
 XX
 PR 12-SEP-1995; 95US-0527056.
 PR 06-MAR-1995; 95US-0400983.
 PR 07-JUN-1995; 95US-0484262.
 XX
 XX (HONG-) HONGTEN PHARM INC.
 XX
 PI Andablibi A, Basu A, Fagan P, Gärten BE, Houghten RA;
 PI Loullis CC, Omholt P, Suto MJ, Tuttle RR, Weber PA;
 DR WPI; 1996-425217/42.
 XX
 XX Cytokine regulatory agents modified at the amino or carboxy terminus
 PT - for controlling e.g. diabetes, obesity, septic shock, side
 PT effects of cancer therapy
 XX
 PS Claim 17; Page 76; 90pp; English.
 XX
 CC The sequences given in AAM00266-72 represent cytokine regulatory
 CC peptides which are modified at the amino or carboxy terminus. These
 CC peptides are used to enhance or restrain cytokine activity and to treat
 CC e.g. disuse deconditioning, IL-10 activity diseases mediated by nitric
 CC oxide and cytokines, adverse drug reactions, obesity, septic shock and
 CC adverse side effects due to cancer chemotherapy or occurring as in
 CC response to organ transplantation, immune, inflammatory and healing
 CC process disorders, pain, cachexia, adult respiratory distress syndrome
 CC (ARDS), autoimmune diseases esp. allergic reactions or anaphylaxis,
 CC arthritis, inflammatory bowel disease, diabetes, glomerulonephritis,
 CC systemic lupus erythematosus, transplant, atherosclerosis and parasitic
 CC mediated immune dysfunctions such as charged disease, esp. organ damage
 CC caused by ischemia reperfusion or immunosuppressant partic. cyclosporin.
 CC The peptides also act to increase the oxygen consumption of a subject.
 CC
 XX
 SQ Sequence 4 AA;
 OY Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 11
 DB 3 RW 4
 RESULT 34
 AAR98545
 ID AAR98545 standard; Peptide; 4 AA.
 XX
 AC AAR98545;

XX DT 12-NOV-1996 (first entry)
 XX
 DE Peptide for anti-ulcer agent.
 XX
 KW anti-ulcer agent; low toxicity; stable; heat-resistant.
 KW
 XX Synthetic.
 OS
 XX JP08143468-A.
 PN
 XX
 PD 04-JUN-1996.
 XX
 PF 17-NOV-1994; 94JP-0283869.
 XX
 PR 17-NOV-1994; 94JP-0283869.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 DR WPI; 1996-318857/32.
 XX
 PT Anti-ulcer agent contg. peptide - has low toxicity, is
 PT heat-resistant and water-soluble
 XX
 PS Claim 1; Page 9; 11pp; Japanese.
 XX
 CC AAR98531-54 are peptides used in an anti-ulcer agent. The agent is low
 CC in toxicity, is heat-resistant and stable in aqueous soln.. It can be
 CC administered orally and be produced in large amounts.
 XX
 SQ Sequence 4 AA;
 OY Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 RW 2
 11
 DB 2 RW 3
 RESULT 35
 AAR98550
 ID AAR98550 standard; Peptide; 4 AA.
 XX
 AC AAR98550;
 XX
 DT 12-NOV-1996 (first entry)
 XX
 DE Peptide for anti-ulcer agent.
 XX
 KW anti-ulcer agent; low toxicity; stable; heat-resistant.
 KW
 XX Synthetic.
 OS
 XX JP08143468-A.
 PN
 XX
 PD 04-JUN-1996.
 XX
 PF 17-NOV-1994; 94JP-0283869.
 XX
 PR 17-NOV-1994; 94JP-0283869.
 XX
 PA (MORG) MORINAGA MILK IND CO LTD.
 DR WPI; 1996-318857/32.
 XX
 PT Anti-ulcer agent contg. peptide - has low toxicity, is
 PT heat-resistant and water-soluble
 XX
 PS Claim 1; Page 10; 11pp; Japanese.
 XX
 CC AAR98531-54 are peptides used in an anti-ulcer agent. The agent is low

CC in toxicity, is heat-resistant and stable in aqueous soln.. It can be
 CC administered orally and be produced in large amounts.

XX Sequence 4 AA;

Query Match 100.0%; Score 16; DB 17; Length 4;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2

DB 2 RW 3

RESULT 36

AAR91850

ID AAR91850 standard; peptide; 4 AA.

XX AAR91850;

AC AAR91850;

DE Lactoferrin-derived specific peptide 20, useful for wound healing.

XX Bovine lactoferrin; wound healing; skin damage; burn; bed sore.

XX Synthetic.

PN JP08081387-A.

XX 26-MAR-1996.

PF 09-SEP-1994; 94JP-0241894.

PR 09-SEP-1994; 94JP-0241894.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-217187/22.

PT Wound healing agent comprising specific peptide(s) - is heat

PT resistant, stable in aqueous solution and suitable for oral,

PT external or subcutaneous admin.

PS Claim 1; Page 10; 12pp; Japanese.

CC The present peptide is useful in a novel wound healing agent. The

CC agent is thermostable and stable in aqueous solution. It is

CC administered externally, orally or subcutaneously for treatment of

CC skin damage such as burns or bedsores.

XX Sequence 4 AA;

Query Match 100.0%; Score 16; DB 17; Length 4;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2

DB 2 RW 3

RESULT 37

AAR91846

ID AAR91846 standard; peptide; 4 AA.

XX AAR91846;

AC AAR91846;

DE Lactoferrin-derived specific peptide 15, useful for wound healing.

XX Bovine lactoferrin; wound healing; skin damage; burn; bed sore.

XX Synthetic.

PN JP08081387-A.

XX 26-MAR-1996.

PF 09-SEP-1994; 94JP-0241894.

PR 09-SEP-1994; 94JP-0241894.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-217187/22.

PT Wound healing agent comprising specific peptide(s) - is heat

PT resistant, stable in aqueous solution and suitable for oral,

PT external or subcutaneous admin.

PS Claim 1; Page 9; 12pp; Japanese.

CC The present peptide is useful in a novel wound healing agent. The

CC agent is thermostable and stable in aqueous solution. It is

CC administered externally, orally or subcutaneously for treatment of

CC skin damage such as burns or bedsores.

XX Sequence 4 AA;

Query Match 100.0%; Score 16; DB 17; Length 4;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2

DB 2 RW 3

RESULT 38

AAR90599

ID AAR90599 standard; peptide; 4 AA.

XX AAR90599;

AC AAR90599;

DE Lactoferrin derived peptide #15.

XX Lactoferrin; antitumour; therapy; tumour; parenteral administration;

XX thermostable; cytotoxic; antibacterial.

XX Synthetic.

PN JP07309771-A.

XX 28-NOV-1995.

PF 17-MAY-1994; 94JP-0103109.

PR 17-MAY-1994; 94JP-0103109.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-045317/05.

PT Antitumour agent, derived from lactoferrin, for parenteral

PT administration - has few side effects and is thermally stable and

PT water soluble

PS Claim 1; Page 7; 10pp; Japanese.

CC AAR90585-R90613 represent lactoferrin derived peptides. These sequences

CC can be used as antitumour agents for parenteral administration. The

CC sequences are thermally stable, water soluble and stable in water.

CC These peptide sequences are only cytotoxic to tumour cells.
 CC Administration of these sequences results in few side effects. No
 CC antiseptic is required for administration due to the antibacterial action
 CC of the peptide. Drugs made from these peptides can be rapidly
 CC metabolised.

XX Sequence 4 AA:

Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
 II
 DB 2 RW 3

RESULT 39

AA890604 standard; peptide; 4 AA.

AC AAR90604;

DT 09-JUL-1996 (first entry)

DE Lactoferrin derived peptide #20.

KW Lactoferrin; antitumour; therapy; tumour; parenteral administration;

KM thermostable; cytotoxic; antibacterial.

OS Synthetic.

PN JP07309771-A.

PD 28-NOV-1995.

PF 17-MAY-1994; 94JP-0103109.

PR 17-MAY-1994; 94JP-0103109.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-045317/05.

PT Antitumour agent, derived from lactoferrin, for parenteral

PT administration - has few side effects and is thermally stable and

PS Claim 1; Page 8; 10pp; Japanese.

CC AAR90585-R90613 represent lactoferrin derived peptides. These sequences
 CC can be used as antitumour agents for parenteral administration. The
 CC sequences are thermally stable, water soluble and stable in water.

CC These peptide sequences are only cytotoxic to tumour cells.

CC Administration of these sequences results in few side effects. No
 CC antiseptic is required for administration due to the antibacterial action
 CC of the peptide. Drugs made from these peptides can be rapidly
 CC metabolised.

XX Sequence 4 AA:

Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
 II
 DB 2 RW 3

RESULT 40

AA87613 standard; peptide; 4 AA.

XX AAR87613;

DT 11-JUL-1996 (first entry)

DE Lactoferrin-derived anti-fungal peptide.

KW Anti-fungal; water soluble; lactoferrin; stable; anti-bacterial;

KM rapidly metabolised.

OS Synthetic.

PN JP07309774-A.

PD 28-NOV-1995.

PF 17-MAY-1994; 94JP-0126882.

PR 17-MAY-1994; 94JP-0126882.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-045320/05.

PT Water-soluble anti-fungus agent derived from lactoferrin - has
 PT antibacterial action and is not cytotoxic to animal cells

PS Claim 1; Page 8; 11pp; Japanese.

CC AAR87599-R87627 are the active ingredients of an anti-fungal agent.
 CC The agent has anti-bacterial as well as anti-fungal properties but is
 CC only cytotoxic to fungal cells. The agent is water-soluble, hence
 CC drugs made from the agent are rapidly metabolised. The peptides are
 CC derived from fragmented lactoferrin.

XX Sequence 4 AA:

Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
 II
 DB 2 RW 3

RESULT 41

AA87618 standard; peptide; 4 AA.

AC AAR87618;

DT 11-JUL-1996 (first entry)

DE Lactoferrin-derived anti-fungal peptide.

KW Anti-fungal; water soluble; lactoferrin; stable; anti-bacterial;

KM rapidly metabolised.

OS Synthetic.

PN JP07309774-A.

PD 28-NOV-1995.

PF 17-MAY-1994; 94JP-0126882.

PR 17-MAY-1994; 94JP-0126882.

PA (MORG) MORINAGA MILK IND CO LTD.

DR WPI; 1996-045320/05.

PR Water-soluble anti-fungus agent derived from lactoferrin - has
 PR antibacterial action and is not cytotoxic to animal cells
 XX
 PS Claim 1; Page 8; 11pp; Japanese.
 XX
 CC AAR87599-887627 are the active ingredients of an anti-fungal agent.
 CC The agent has anti-bacterial as well as anti-fungal properties but is
 CC only cytotoxic to fungal cells. The agent is water-soluble, hence
 CC drugs made from the agent are rapidly metabolised. The peptides are
 CC derived from fragmented lactoferrin.
 CC
 SQ Sequence 4 AA;
 Query Match 100.0%; Score 16; DB 17; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 11
 DB 2 RW 3
 RESULT 42
 AAM45420
 ID AAM45420 standard; peptide; 4 AA.
 XX
 AC AAM45420;
 XX
 DT 14-MAY-1998 (first entry)
 XX
 DE Cytokine regulatory agent #1.
 XX
 KW Cytokine regulatory agent; oral administration; ion exchange resin;
 KM degradation.
 XX
 OS Synthetic.
 XX
 FT Key Location/Qualifiers
 FT Modified-site 1 /note= "Optional N-terminal acetyl"
 FT Misc-difference 2 /note= "D-form residue"
 FT Misc-difference 4 /note= "D-form residue, optional C-terminal amide"
 FT
 FT WO9722356-A1.
 XX
 PN 26-JUN-1997.
 XX
 PD 18-DEC-1996; 96WO-US20378.
 XX
 PE 19-DEC-1995; 95US-0574556.
 XX
 PR (HUGH-) HUGHEN PHARM INC.
 XX
 PA Manitar M, Mauch S;
 PI
 PL WPI; 1997-341431/31.
 DR
 XX
 XX Complex of ion exchange resin with bio-polymer drug - especially
 PR cytokine regulatory peptide, protecting drug against enzymatic
 FT degradation on oral administration
 XX
 PS Disclosure; Page 12; 36pp; English.
 XX
 CC This sequence represents a cytokine regulatory agent peptide. The
 CC invention relates to a novel composition which comprises an ion exchange
 CC resin and a therapeutically effective biopolymer in a form for oral
 CC administration. This invention provides a method of protecting a
 CC therapeutically active bioactive polymer from degradation. These
 CC compounds are useful for oral administration of drugs e.g. of a nucleic
 CC acid to the small or large intestine to modulate the expression of
 CC cellular gene products or treatment of colon cancer or especially for

CC administration of a cytokine regulatory agent (CRA) peptide to control
 CC aberrant cytokine activity, as occurs in pathological conditions such as
 CC immune and inflammatory responses. The release characteristics of the
 CC biopolymer from the compound in the small or large intestine can be
 CC controlled by selection of the ion exchange resin and optional use of
 CC coatings.
 CC
 SQ Sequence 4 AA;
 Query Match 100.0%; Score 16; DB 18; Length 4;
 Best Local Similarity 100.0%; Pred. No. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 RW 2
 11
 DB 3 RW 4
 RESULT 43
 AAM30863
 ID AAM30863 standard; peptide; 4 AA.
 XX
 AC AAM30863;
 XX
 DT 08-APR-1998 (first entry)
 XX
 DE Analgesic N-terminal substituted tetrapeptide #8.
 XX
 KW Analgesic agent; high potency; trityl; tetrapeptide.
 XX
 OS Synthetic.
 XX
 FT Key Location/Qualifiers
 FT Modified-site 1 /note= "Trityl-Asn"
 FT Modified-site 4 /note= "C-terminal amide"
 FT
 FT WO9733907-A1.
 XX
 PN 18-SEP-1997.
 XX
 PD 10-MAR-1997; 97WO-JP00751.
 XX
 PE 11-MAR-1996; 96JP-0053353.
 XX
 PR (SAKA) OTSUKA PHARM CO LTD.
 XX
 PA Adachi M, Aimoto S, Kanemoto N, Kuwahara M, Muneoka Y;
 PI Ogino K;
 PI
 PL WPI; 1997-479891/44.
 DR
 XX
 XX Analgesic N-terminal substituted trl- and tetrapeptide(s) - where
 PR the N-terminal substituent contains one or more benzene ring and is
 FT preferably trityl
 XX
 PS Example 1; Page 25; 122pp; English.
 XX
 CC The present sequence represents a specific example of a tetrapeptide
 CC derivative which is useful as an analgesic agent with high potency.
 CC The tetrapeptides have the formula; X1(R)-X2-X3-X4-A; where X1 = Asn,
 CC Gln, His, Ser, Thr or Cys; R = a functional group containing a benzene
 CC ring, such as trityl (preferred), diphenylmethyl, tris(p-hydroxyphenyl)-
 CC methyl or benzyl; X2 = Gln, Met, Leu, Arg, His, Gly, Thr or Cys; X3 =
 CC any genetically encodable amino acid; X4 = a direct bond or any
 CC genetically encodable amino acid; A = C-terminal OH or NH2 or a
 CC substituted group derived from them, such as NHNH2, NHHNCOCH2S,
 CC NHC(CH2CH2N)(CH3)2, NH(CH2)3S(O)CH3, NH(CH2)8NH2 or NH(CH2)7CONH2.
 CC
 SQ Sequence 4 AA;
 Query Match 100.0%; Score 16; DB 18; Length 4;

Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
11
DB 3 RW 4

RESULT 44
AAW30473
ID AAW30473 standard; peptide; 4 AA.
XX
AC AAW30473;
XX
DT 06-FEB-1998 (first entry)
XX
DE Cytokine regulatory agent #3.
XX
KM Cytokine regulatory agent; CRA; cytokine restraining agents; GI damage;
KM gastro-intestinal damage; non-steroidal anti-inflammatory drug; therapy;
KW NSAID; indomethacin; chronic disease; hereditary disease; cyclic;
KW Crohn's disease; ulcerative colitis.
XX
OS Synthetic.
XX
FH Key
FH Misc-difference 1..4 Location/Qualifiers
FT Misc-difference 2 /note= "optionally form cyclic peptide"
FT Misc-difference 2 /note= "D-form residue"
FT Misc-difference 4 /note= "D-form residue"
XX
PN WO9709995-A1.
XX
PD 20-MAR-1997.
XX
PF 12-SEP-1996; 96WO-US14744.
XX
PR 12-SEP-1995; 95US-0527252.
XX
PA (HONG-) HONGTEN PHARM INC.
XX
PI Gilden BE, Omholt P, Tuttle RR;
XX
DR WPI; 1997-202003/18.
XX
PT Reducing severity of gastro-intestinal damage - by administration of
PT cytokine regulatory agent
XX
PS Claim 22; Page 19; 22pp; English.
XX
CC AAW30470-W30474 represent cytokine regulatory elements (CRAs) used in
CC the method of the invention. CRAs were previously known as cytokine
CC restraining agents. The method of the invention is for reducing the
CC severity of gastro-intestinal (GI) damage in an individual susceptible
CC for developing such damage. The method comprises administering to the
CC individual an effective dose of a CRA of formula
CC X1-X2-His-(D)Phe-Arg-(D)Tyr-X3 (I) or X4-X5-(D)Phe-Arg-(D)Tyr-X3' (II),
CC in which X1= a group of formula R2R1N-CHR3-C(Y1)(Y2)-(11), H or COCH3;
CC X2= a group of formula -NR1-CHR4-C(Y1)(Y2)-(11); X3= R3 or a group of
CC formula -NR1-CHR6-(CH2)n-C(Y1)(Y2)-R5 (11); X4= H, COCH3, or group of
CC formula R1R2N-CHR4-C(Y1)(Y2)-(1v), or is absent; X5= His, H or COCH3;
CC X3'= NH2, OH or a group (111); Y1, Y2= H or together form a carbonyl
CC or thiocarbonyl; R1= H, COCH3, C2H5, CH2Ph, COPh, COOCH2Ph, COO-t-butyl,
CC CH2CO-(polyethylene glycol) or A; R2= H or COCH3; R3= 1-6C linear or
CC branched alkyl, or 3-6C cyclic alkyl; R4= (CH2)mCONH2, (CH2)m-CONHR1 or
CC (CH2)m-CONHA; R5= OH, OR3, NH2, SH, NHCH3, NHCH2Ph or A; R6= H or R3;
CC Ph= C6H5; m= 1-3; n= 0-3; and A= a carbohydrate. The method can be
CC used to reduce the severity of GI damage induced by a non-steroidal
CC anti-inflammatory drug (NSAID), e.g. indomethacin. The GI damage treated
CC with these sequences can also occur as a result of chronic or hereditary
CC diseases such as ulcerative colitis, or Crohn's disease.

XX SQ Sequence 4 AA;
Query Match 100.0%; Score 16; DB 18; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
11
DB 3 RW 4

RESULT 45
AAW26144
ID AAW26144 standard; peptide; 4 AA.
XX
AC AAW26144;
XX
DT 24-NOV-1997 (first entry)
XX
DE Lactoferrin derivative #13.
XX
KM Lactoferrin; lactoferrin hydrolysate; derivative; neovascular disease;
KM opthalamic disease; chronic rheumatism; abnormal capillary vessel;
KW psoriasis; therapy.
XX
OS Synthetic.
XX
PN JP09194388-A.
XX
PD 29-JUL-1997.
XX
PF 22-JAN-1996; 96JP-0008722.
XX
PR 22-JAN-1996; 96JP-0008722.
XX
PA (MORG) MORINAGA MILK IND CO LTD.
XX
DR WPI; 1997-431405/40.
XX
PT Peptide derived from lactoferrin or lactoferrin hydrolysate - for
PT treatment of neovascular diseases
XX
PS Claim 3; Page 8; 11pp; Japanese.
XX
CC AAW26132-W26157 represent the peptide derivatives of the invention.
CC These sequences are derivatives of lactoferrin or lactoferrin
CC hydrolysate. The derivatives are used in an agent for the treatment of
CC neovascular diseases. The diseases that the peptides can be used to treat
CC include opthalamic diseases, chronic rheumatism, psoriasis and abnormal
CC capillary vessels.
XX
SO Sequence 4 AA;
Query Match 100.0%; Score 16; DB 18; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 RW 2
11
DB 2 RW 3

RESULT 46
AAW26148
ID AAW26148 standard; peptide; 4 AA.
XX
AC AAW26148;
XX
DT 24-NOV-1997 (first entry)
XX
DE Lactoferrin derivative #17.
XX

KW lactoferrin; lactoferrin hydrollysate; derivative; neovascular disease;
 KM ophthalmic disease; chronic rheumatism; abnormal capillary vessel;
 KM psoriasis; therapy.
 OS Synthetic.
 XX JP09194388-A.
 PN 29-JUL-1997.
 XX 22-JAN-1996; 96JP-0008722.
 PF 22-JAN-1996; 96JP-0008722.
 PR 22-JAN-1996; 96JP-0008722.
 XX (MORG) MORINAGA MILK IND CO LTD.
 PA WPI; 1997-431405/40.
 DR Peptide derived from lactoferrin or lactoferrin hydrollysate - for
 PT treatment of neovascular diseases
 PS Claim 3; Page 8; 11pp; Japanese.
 XX AAW26132-W26157 represent the peptide derivatives of the invention.
 CC These sequences are derivatives of lactoferrin or lactoferrin
 CC hydrollysate. The derivatives are used in an agent for the treatment of
 CC neovascular diseases. The diseases that the peptides can be used to treat
 CC include ophthalmic diseases, chronic rheumatism, psoriasis and abnormal
 CC capillary vessels.
 XX Sequence 4 AA:
 SQ
 QY Query Match 100.0%; Score 16; DB 18; Length 4;
 Best Local Similarity 100.0%; Pred. NO. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 RW 2
 2 RW 3
 RESULT 47
 AAW14030
 ID AAW14030 standard; peptide; 4 AA.
 XX AAW14030;
 AC 27-MAY-1997 (first entry)
 DT Anti-parasitic peptide #14.
 XX Anti-parasitic; cytotoxic.
 KM Synthetic.
 OS JP09040578-A.
 PN 10-FEB-1997.
 PD 31-JUL-1995; 95JP-0195218.
 PF 31-JUL-1995; 95JP-0195218.
 PR 31-JUL-1995; 95JP-0195218.
 XX (MORG) MORINAGA MILK IND CO LTD.
 PA WPI; 1997-175617/16.
 DR Anti-parasite agent - shows no cytotoxicity to normal cells
 PT Claim 1; Page 8; 11pp; Japanese.
 PS AAW14017-W14044 represent peptide sequence used in the anti-parasitic
 CC agent of the invention. The anti-parasitic agent contains one of these

CC sequences, or a mixture of at least two of them (or derivatives, or
 CC salts of these sequences) as the active component. The agent is an
 CC anti-parasitic and has low side effects and shows no cytotoxicity to
 CC normal cells. The agent is also stable in aqueous solution.
 XX SQ
 Sequence 4 AA:
 SQ
 QY Query Match 100.0%; Score 16; DB 18; Length 4;
 Best Local Similarity 100.0%; Pred. NO. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 RW 2
 2 RW 3
 RESULT 48
 AAW14034
 ID AAW14034 standard; peptide; 4 AA.
 XX AAW14034;
 AC 27-MAY-1997 (first entry)
 DT Anti-parasitic peptide #18.
 XX Anti-parasitic agent; cytotoxic; parasite.
 KM Synthetic.
 OS JP09040578-A.
 PN 10-FEB-1997.
 PD 31-JUL-1995; 95JP-0195218.
 PF 31-JUL-1995; 95JP-0195218.
 PR 31-JUL-1995; 95JP-0195218.
 XX (MORG) MORINAGA MILK IND CO LTD.
 PA WPI; 1997-175617/16.
 DR Anti-parasite agent - shows no cytotoxicity to normal cells
 PT Claim 1; Page 8; 11pp; Japanese.
 PS AAW14017-W14044 represent peptide sequence used in the anti-parasitic
 CC agent of the invention. The anti-parasitic agent contains one of these
 CC sequences, or a mixture of at least two of them (or derivatives, or
 CC salts of these sequences) as the active component. The agent is an
 CC anti-parasitic and has low side effects and shows no cytotoxicity to
 CC normal cells. The agent is also stable in aqueous solution.
 XX SQ
 Sequence 4 AA:
 SQ
 QY Query Match 100.0%; Score 16; DB 18; Length 4;
 Best Local Similarity 100.0%; Pred. NO. 7.8e+05;
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 1 RW 2
 2 RW 3
 RESULT 49
 AAY21340
 ID AAY21340 standard; Protein; 4 AA.
 XX AAY21340;
 AC 22-JUL-1999 (first entry)
 DT Human semaphorin III mutant protein fragment 73.

```

XX Human; beta-amyloid precursor protein; beta-ApP; diagnosis; cancer;
KW frameshift mutation; age-related disease; neurodegenerative disorder;
KW Alzheimer's disease; Down's syndrome; myotonic dystrophy; neuronal;
KW Huntington's disease; multiple sclerosis; alcoholic liver disease;
KW diabetes mellitus type II; microtubule associated protein; Tau; Big Tau;
KW ubiquitin B; apolipoprotein E; MAP2; neurofilament-L; neurofilament-M;
KW neurofilament-F; presenilin I; presenilin II; cellular tumour antigen;
KW glial fibrillary acidic protein; GFAP; p53; semaphorin III; HUPF-1;
KW bcl-2; B-cell leukemia/lymphoma 2 proto-oncogene; HMGP-C; NSP-A;
KW high mobility group protein-C; neuroendocrine specific protein A.
XX
OS Synthetic.
OS Homo sapiens.
PN WO9845322-A2.
XX
PD 15-OCT-1998.
XX
PF 02-APR-1998; 98WO-IB00705.
XX
PR 10-APR-1997; 97US-0043163.
XX
PA (UYVE-) RIJKSUNIV UMRECHT.
PA (ROYA-) ROYAL NETHERLANDS ACAD ARTS & SCI.
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Burbach JPH, Grosveld FG, Van Leeuwen FW;
XX
DR WPI: 1998-609901/51.
DR N-ESDB: AAX75767.
XX
PT Diagnosing disease by detecting frameshift mutations in RNA or
PT corresponding protein mutations - used to diagnose cancer and
PT neurological diseases, particularly Alzheimer's disease, and also
PT for treatment and prevention with specific ribozymes or wild-type
PT RNA
XX
PS Disclosure; Figure 16; 258pp; English.
XX
CC This invention describes a novel method for the diagnosis of a disease
CC caused by, or associated with, an RNA molecule that has a frameshift
CC mutation. The method is used to diagnose age-related diseases, especially
CC cancer and a wide range of neurodegenerative disorders (e.g. Alzheimer's
CC disease, Down's syndrome, myotonic dystrophy, Huntington's disease,
CC multiple sclerosis, alcoholic liver disease, diabetes mellitus type II
CC and many others listed) or susceptibility to these disorders. The method
CC allows a definitive diagnosis of Alzheimer's disease in living patients,
CC at an early stage. It is based on the observation that disease may be
CC caused by mutations in RNA rather than DNA. The invention describes the
CC use of neuronal system RNA molecules, specifically proteins including
CC beta-amyloid precursor protein (beta-ApP), the microtubule associated
CC proteins Tau and Big Tau, ubiquitin B, apolipoprotein E, microtubule
CC associated protein 2 (MAP2), neurofilament-L, neurofilament-M,
CC neurofilament-F, presenilin I, presenilin II, glial fibrillary acidic
CC protein (GFAP), the cellular tumour antigen p53, B-cell leukemia/lymphoma
CC 2 (bcl-2) proto-oncogene, semaphorin III, HUPF-1, high mobility group
CC protein-C (HMGP-C) and neuroendocrine specific protein A.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 16; DB 19; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RW 2
11
DB 2 RW 3

```

RESULT 50
AAM70295
ID AAM70295 standard; peptide; 4 AA.

```

XX AC AAM70295;
XX XX
DR 06-NOV-1998 (first entry)
XX
DE Thrombus formation inhibitory peptide derivative 1.
XX
KW Polyethyleneglycol; PEG; thrombus; side effect; inhibitory peptide.
XX
OS Synthetic.
XX
TH Key Location/Qualifiers
FT Modified-site 1 /note= "Optionally attached by CH3(CH2)4CO-,
FT CH3(CH2)8CO- and CH3CH(OH)CO- groups"
FT Misc-difference 1 /note= "D-form residue"
FT Misc-difference 2 /note= "D-form residue"
FT Misc-difference 3 /note= "D-form residue"
FT Misc-difference 4 /note= "D-form residue"
FT Misc-difference 4 /note= "D-form residue"
FT Modified-site 4 /note= "Optional C-terminal amide"
FT
XX
PN JP10182479-A.
XX
PD 07-JUL-1998.
XX
PF 24-DEC-1996; 96JP-0343590.
XX
PR 24-DEC-1996; 96JP-0343590.
XX
PA (MORG ) MORINAGA MILK IND CO LTD.
XX
DR WPI: 1998-433772/37.
XX
PT Drug comprises peptide derivative used to inhibit thrombus formation
PT - optionally combined with and/or adsorbed onto carrier, has low
PT side effects
XX
PS Examples 1-4; Page 7; 14pp; Japanese.
XX
CC The invention provides a drug composition comprising of a peptide
CC derivative of the formula (A) R1X, (B) XR2 or (C) R1XR2; where
CC R1 = acyl or polyethyleneglycol (PEG); R2 = amino, acyl, PEG or
CC beta-alanine-PEG; X = peptide sequence of 3-47 D or L amino acids
CC such as the present sequence. The drug is claimed to inhibit
CC thrombus formation with low side effect.
XX
SQ Sequence 4 AA;
XX
Query Match 100.0%; Score 16; DB 19; Length 4;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 RW 2
11
DB 1 RW 2

```

Search completed: February 21, 2003, 12:30:55
Job time : 39 secs

